Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name CPL304110
Synonyms
Therapy Description

CPL304110 inhibits FGFR1, 2, and 3, which may inhibit FGFR signaling pathways, proliferation, and tumor growth (PMID: 33199155).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CPL304110 CPL-304110 FGFR1 Inhibitor 28 FGFR2 Inhibitor 23 FGFR3 Inhibitor 19 CPL304110 inhibits FGFR1, 2, and 3, which may inhibit FGFR signaling pathways, proliferation, and tumor growth (PMID: 33199155).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 amp stomach cancer sensitive CPL304110 Preclinical - Pdx & cell culture Actionable In a preclinical study, CPL304110 inhibited Erk phosphorylation and viability in an FGFR2-amplified gastric cancer cell line in culture, inhibited growth in a cell line xenograft model, and induced tumor regression in a patient-derived xenograft (PDX) model (PMID: 38282676). 38282676
FGFR2 amp lung non-small cell carcinoma sensitive CPL304110 Preclinical - Pdx Actionable In a preclinical study, CPL304110 inhibited tumor growth in a patient-derived xenograft (PDX) model of FGFR2-amplified non-small cell lung cancer, however, regrowth was observed after treatment was stopped (PMID: 38282676). 38282676
FGFR1 amp lung non-small cell carcinoma sensitive CPL304110 Preclinical - Cell culture Actionable In a preclinical study, CPL304110 treatment inhibited proliferation of a non-small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 33199155). 33199155
FGFR3 fusion FGFR3 amp bladder carcinoma sensitive CPL304110 Preclinical - Cell culture Actionable In a preclinical study, CPL304110 treatment inhibited proliferation of a bladder carcinoma cell line harboring FGFR3 amplification and an FGFR3 fusion in culture (PMID: 33199155). 33199155
FGFR2 amp stomach carcinoma sensitive CPL304110 Preclinical - Cell line xenograft Actionable In a preclinical study, CPL304110 treatment inhibited downstream signaling and proliferation of a gastric carcinoma cell line harboring FGFR2 amplification in culture and inhibited tumor growth in cell line xenograft models (PMID: 33199155). 33199155
FGFR3 S249C urinary bladder cancer sensitive CPL304110 Preclinical - Cell line xenograft Actionable In a preclinical study, CPL304110 inhibited Erk phosphorylation in a bladder cancer cell line harboring FGFR3 S249C in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38282676). 38282676
FGFR3 S249C bladder carcinoma sensitive CPL304110 Preclinical - Cell culture Actionable In a preclinical study, CPL304110 treatment inhibited proliferation of a bladder carcinoma cell line harboring FGFR3 S249C in culture (PMID: 33199155). 33199155
FGFR2 amp endometrial cancer sensitive CPL304110 Preclinical - Cell culture Actionable In a preclinical study, CPL304110 inhibited viability of an FGFR2-amplified endometrial cancer cell line in culture (PMID: 38282676). 38282676

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries


Additional content available in CKB BOOST